Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New DrugEsperion Therapeutics' proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.

More From CBS Detroit

Hump Day Drinks: 8 Cheery Cocktail RecipesNow that you've made it through half the work week, it's time to celebrate!
Daily J

Watch & Listen